INOVIO Reports Inducement Grant Under Inducement Plan

Rhea-AI Summary

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced an equity grant under its 2022 Inducement Plan to a newly hired employee. The Compensation Committee approved a stock option award to purchase 1,302 shares of common stock with an exercise price of $2.34 per share, effective September 30, 2025.

The stock option will vest over three years, with one-third of shares vesting annually on the grant date anniversary. Vesting is contingent upon continued employment with INOVIO.

News Market Reaction

+3.80%

1 alert

+3.80% News Effect

+$5M Valuation Impact

$126M Market Cap

3K Volume

On the day this news was published, INO gained 3.80%, reflecting a moderate positive market reaction. This price movement added approximately $5M to the company's valuation, bringing the market cap to $126M at that time.

Data tracked by StockTitan Argus on the day of publication.

PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved the award of an option to purchase 1,302 shares of common stock with a grant date of September 30, 2025 (the "Grant Date"), to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.34, the closing price of INOVIO's common stock on September 30, 2025. The stock option will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreement under the Inducement Plan.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, 443-213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302573337.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What is the exercise price of INOVIO's (INO) new stock option grant?

The stock option has an exercise price of $2.34, which was INOVIO's closing stock price on September 30, 2025.

How many shares are included in INOVIO's (INO) new employee stock option grant?

The stock option grant allows for the purchase of 1,302 shares of common stock.

What is the vesting schedule for INOVIO's (INO) new employee stock option grant?

The stock option vests over three years, with one-third of the shares vesting on each of the first, second, and third anniversaries of the September 30, 2025 grant date.

What is INOVIO's 2022 Inducement Plan?

The 2022 Inducement Plan is INOVIO's equity compensation program used to grant stock options to newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4).